ELI LILLY AND COMPANY |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 706.2 EUR | -0.86% |
|
-0.28% | +34.55% |
| May. 10 | Cipla Open to Partner With Eli Lilly to Market Obesity Drugs in India | MT |
| May. 10 | Roughly 1 in 8 US adults have taken GLP-1 drugs like Wegovy, poll shows | RE |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 42.81B 39.68B | Sales 2025 * | 52.47B 48.63B | Capitalization | 684B 634B |
|---|---|---|---|---|---|
| Net income 2024 * | 11.93B 11.06B | Net income 2025 * | 16.55B 15.34B | EV / Sales 2024 * | 16.5 x |
| Net Debt 2024 * | 19.98B 18.52B | Net Debt 2025 * | 15.29B 14.17B | EV / Sales 2025 * | 13.3 x |
| P/E ratio 2024 * |
56.8
x | P/E ratio 2025 * |
40.9
x | Employees | 43,000 |
| Yield 2024 * |
0.68% | Yield 2025 * |
0.79% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | -0.86% | ||
| 1 week | -0.28% | ||
| Current month | -2.55% | ||
| 1 month | +0.04% | ||
| 3 months | +2.37% | ||
| 6 months | +25.60% | ||
| Current year | +34.55% |
1 week
707.50
726.90
1 month
670.00742.80
Current year
529.00742.80
1 year
387.40742.80
3 years
158.20742.80
5 years
94.66742.80
10 years
42.19742.80
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 00-12-31 |
Ruth Gimeno
PSD | President | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 04-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-13 | 708.4 | -0.55% | 138 |
| 24-05-10 | 712.3 | -1.40% | 324 |
| 24-05-09 | 722.4 | +0.12% | 38 |
| 24-05-08 | 721.5 | -0.19% | 366 |
| 24-05-07 | 722.9 | +1.76% | 567 |
Delayed Quote Deutsche Boerse AG, May 13, 2024 at 06:55 am EDT
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
760
USD
Average target price
850.4
USD
Spread / Average Target
+11.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +29.27% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +15.95% | 240B | |
| +9.38% | 208B | |
| -7.32% | 200B | |
| +7.68% | 166B | |
| -2.71% | 159B |
- Stock Market
- Equities
- LLY Stock
- LLY Stock
